Michael Andrew Rogawski MD PhD
Distinguished Professor, School of Medicine, University of California, Davis
Join to View Full Profile
4860 Y StSte 3700Sacramento, CA 95817
Phone+1 916-734-6275
Fax+1 916-724-6526
Dr. Rogawski is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Johns Hopkins UniversityResidency, Neurology, 1984 - 1986
Clinical Center at the National Institutes of HealthResidency, Neurology, 1983 - 1984- Johns Hopkins UniversityResidency, Neurology, 1982 - 1983
- Clinical Center at the National Institutes of HealthResidency, Neurology, 1981 - 1982
University of Connecticut (Waterbury)Internship, Internal Medicine, 1980 - 1981
Certifications & Licensure
CA State Medical License 2007 - 2027
MD State Medical License 1982 - 2007
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2011, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2011, 2013-2015, 2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2012
Clinical Trials
- Efficacy and Safety of the Use of Memantine for Preserving Cognition in Adult Patients With Epilepsy Start of enrollment: 2010 Jul 01
- Allopregnanolone for the Treatment of Traumatic Brain Injury Start of enrollment: 2013 Apr 01
Publications & Presentations
PubMed
- 1 citationsENX-101, a GABAreceptor α2,3,5-selective positive allosteric modulator, displays antiseizure effects in rodent seizure and epilepsy models.Jordi Serrats, Krishna C Vadodaria, William Brubaker, Melissa Barker-Haliski, H Steve White
Epilepsia. 2025-06-01 - 4 citationsInterim analysis of the long-term efficacy and safety of azetukalner in an ongoing open-label extension study following a phase 2b clinical trial (X-TOLE) in adults wi...Jacqueline A French, Roger J Porter, Emilio Perucca, Martin J Brodie, Michael A Rogawski
Epilepsia Open. 2025-04-01 - 1 citationsAllopregnanolone as an Adjunct Therapy to Midazolam is More Effective Than Midazolam Alone in Suppressing Soman-Induced Status Epilepticus in Male Rats.Peter M Andrew, Jeremy A MacMahon, Xiuzhen Liu, Naomi H Saito, Kyle E Berger
CNS Neuroscience & Therapeutics. 2025-03-01
Lectures
- 15th Annual Meeting of American Society for Experimental NeuroTherapeutics: ASENT 2013American Society for Experimental NeuroTherapeutics(ASENT), Bethesda, Maryland - 2/28/2013
- Neurology Update 2012: Practical Information for the Primary Care ProviderUC Davis Health System, Sacramento, California - 5/19/2012
Press Mentions
Xenon Pharmaceuticals Announces Completion of Patient Randomization in XEN1101 Phase 2b “X-TOLE” Clinical Trial and Announces Upcoming Investor Webinar with Leading Epilepsy Key Opinion LeadersJuly 7th, 2021- Neurologist Michael Rogawski Named Fellow of National Academy of InventorsDecember 9th, 2020
- Celebrating 20 YearsOctober 28th, 2020
Grant Support
- Training in Neurotherapeutics for Academic ScientistsUNIVERSITY OF CALIFORNIA AT DAVIS2022–2027
- UC Davis Clinician Neuroscientist Development ProgramUNIVERSITY OF CALIFORNIA AT DAVIS2022–2027
- Training In Neurotherapeutics Discovery And Development For Academic ScientistsNational Institute Of Neurological Disorders And Stroke2012
- Identification Of Novel Therapeutic Approaches For Tets And OP IntoxicationNational Institute Of Neurological Disorders And Stroke2010–2011
- Ion Channels In Epilepsy And As Targets For AntiepileptiNational Institute Of Neurological Disorders And Stroke2001–2006
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
